iOrganBio, an innovator in intelligent cell manufacturing, announced today the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin, a leading authority in stem cell biology, regenerative medicine, and translational neuroscience, is Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology. His pioneering work spans blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).
The appointment underscores iOrganBio’s commitment to advancing its CellForge platform, which combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency. This platform enables scalable production for disease modeling, drug discovery, and cell therapy development. Dr. Rubin’s extensive academic and entrepreneurial leadership will be key to expanding iOrganBio’s platform in neurological applications, particularly in developing new approach methodologies (NAMs) aligned with FDA standards.
iOrganBio’s CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At its core is the functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality needed to accelerate disease modeling, regenerative medicine, and drug development. For more information, visit iOrgan.Bio.
Dr. Rubin’s appointment is expected to enhance iOrganBio’s capabilities in creating reliable in vitro models for neurological diseases, addressing a critical need for more human-relevant testing methods. As regulatory agencies increasingly emphasize NAMs, iOrganBio’s technology, combined with Dr. Rubin’s expertise, positions the company to provide scalable, consistent cell models that could reduce reliance on animal testing and improve drug development outcomes.
